Patents by Inventor Anthony B. Reed

Anthony B. Reed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20200069657
    Abstract: Provided herein are methods of treating cancer with KRAS G12C inhibitors and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: November 5, 2019
    Publication date: March 5, 2020
    Applicant: AMGEN INC.
    Inventors: Brian Alan LANMAN, Victor J. CEE, Alexander J. PICKRELL, Anthony B. REED, Kevin C. YANG, David John KOPECKY, Hui-Ling WANG, Patricia LOPEZ, Kate ASHTON, Shon BOOKER, Christopher M. TEGLEY
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20200055845
    Abstract: Provided herein are methods of using KRAS G12C inhibitors and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: October 23, 2019
    Publication date: February 20, 2020
    Inventors: Brian Alan LANMAN, Jian CHEN, Anthony B. REED, Victor J. CEE, Longbin LIU, David John KOPECKY, Patricia LOPEZ, Ryan Paul WURZ, Thomas T. NGUYEN, Shon BOOKER, Nobuko NISHIMURA, Youngsook SHIN, Nuria A. TAMAYO, John Gordon ALLEN, Jennifer Rebecca ALLEN
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 10532042
    Abstract: Provided herein are KRAS G12C inhibitors, compounds of formula (II), or a pharmaceutically acceptable salt thereof: compositions of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: January 14, 2020
    Assignee: Amgen Inc.
    Inventors: Brian Alan Lanman, Victor J. Cee, Alexander J. Pickrell, Anthony B. Reed, Kevin C. Yang, David John Kopecky, Hui-Ling Wang, Patricia Lopez, Kate Ashton, Shon Booker, Christopher M. Tegley
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 10519146
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: December 31, 2019
    Assignee: Amgen Inc.
    Inventors: Brian Alan Lanman, Jian Chen, Anthony B. Reed, Victor J. Cee, Longbin Liu, David John Kopecky, Patricia Lopez, Ryan Paul Wurz, Thomas T. Nguyen, Shon Booker, Nobuko Nishimura, Youngsook Shin, Nuria A. Tamayo, John Gordon Allen, Jennifer Rebecca Allen
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20190374542
    Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: June 11, 2019
    Publication date: December 12, 2019
    Inventors: John Gordon ALLEN, Brian Alan LANMAN, Jian CHEN, Anthony B. REED, Victor J. CEE, Longbin LIU, Patricia LOPEZ, Ryan Paul WURZ, Thomas T. NGUYEN, Shon Booker, Jennifer Rebecca ALLEN, Margaret CHU-MOYER, Albert AMEGADZIE, Ning CHEN, Clifford GOODMAN, Jonathan D. LOW, Vu Van MA, Ana Elena MINATTI, Nobuko NISHIMURA, Alexander J. PICKRELL, Hui-Ling WANG, Youngsook SHIN, Aaron C. SIEGMUND, Kevin C. YANG, Nuria A. TAMAYO, Mary WALTON, Qiufen XUE
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20190343838
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: May 3, 2019
    Publication date: November 14, 2019
    Inventors: John Gordon Allen, Jennifer Rebecca Allen, Ana Elena Minatti, Qiufen Xue, Ryan Paul Wurz, Christopher M. Tegley, Alexander J. Pickrell, Thomas T. Nguyen, Vu Van Ma, Patricia Lopez, Longbin Liu, David John Kopecky, Michael J. Frohn, Ning Chen, Jian Jeffrey Chen, Aaron C. Siegmund, Albert Amegadzie, Nuria A. Tamayo, Shon Booker, Clifford Goodman, Mary Walton, Nobuko Nishimura, Youngsook Shin, Jonathan D. Low, Victor J. Cee, Anthony B. Reed, Hui-Ling Wang, Brian Alan Lanman
  • INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME
    Publication number: 20190077801
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 14, 2019
    Inventors: Brian Alan LANMAN, Shon BOOKER, Clifford GOODMAN, Anthony B. REED, Jonathan D. LOW, Hui-Ling WANG, Ning CHEN, Ana Elena MINATTI, Ryan WURZ, Victor J. CEE
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20180334454
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: May 21, 2018
    Publication date: November 22, 2018
    Inventors: Brian Alan LANMAN, Jian CHEN, Anthony B. REED, Victor J. CEE, Longbin LIU, David John KOPECKY, Patricia LOPEZ, Ryan Paul WURZ, Thomas T. NGUYEN, Shon BOOKER, Nobuko NISHIMURA, Youngsook SHIN, Nuria A. TAMAYO, John Gordon ALLEN, Jennifer Rebecca ALLEN
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20180177767
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: December 21, 2017
    Publication date: June 28, 2018
    Applicant: AMGEN INC.
    Inventors: Brian Alan LANMAN, Victor J. CEE, Alexander J. PICKRELL, Anthony B. REED, Kevin C. YANG, David John KOPECKY, Hui-Ling WANG, Patricia LOPEZ, Kate ASHTON, Shon BOOKER, Christopher M. TEGLEY
  • APELIN POLYPEPTIDES
    Publication number: 20170107255
    Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
    Type: Application
    Filed: June 10, 2015
    Publication date: April 20, 2017
    Applicant: AMGEN INC.
    Inventors: Jerry Ryan HOLDER, Gayathri SWAMINATH, Michael J. FROHN, Brian Alan LANMAN, Anthony B. REED, Leslie P. Miranda, John G. Allen, Alexander J. Pickrell, Aaron C. Siegmund, Lewis D. Pennington, Bryant Yang
  • Amides as pim inhibitors
    Patent number: 9394297
    Abstract: The invention relates to amide-containing compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: July 19, 2016
    Assignee: AMGEN INC.
    Inventors: Victor Cee, Frank Chavez, Jr., Jian J. Chen, Essa Hu Harrington, Bradley Herberich, Claire L. M. Jackson, Brian A. Lanman, Thomas T. Nguyen, Mark H. Norman, Liping H. Pettus, Anthony B. Reed, Adrian L. Smith, Nuria A. Tamayo, Andrew Tasker, Hui-Ling Wang, Bin Wu, Ryan Wurz
  • Azole compounds as PIM inhibitors
    Patent number: 9321756
    Abstract: The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: April 26, 2016
    Assignee: AMGEN INC.
    Inventors: Hui-Ling Wang, Victor J. Cee, Bradley J. Herberich, Claire L. M. Jackson, Brian Alan Lanman, Thomas Nixey, Liping H. Pettus, Anthony B. Reed, Bin Wu, Ryan Wurz, Andrew Tasker
  • AMIDES AS PIM INHIBITORS
    Publication number: 20150329538
    Abstract: The invention relates to amide-containing compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Application
    Filed: February 27, 2013
    Publication date: November 19, 2015
    Applicant: AMGEN INC.
    Inventors: Victor CEE, Frank CHAVEZ, JR., Jian J. CHEN, Essa Hu HARRINGTON, Bradley HERBERICH, Claire L.M. JACKSON, Brian A. LANMAN, Thomas T. NGUYEN, Mark H. NORMAN, Liping H. PETTUS, Anthony B. REED, Adrian L. SMITH, Nuria A. TAMAYO, Andrew TASKER, Hui-Ling WANG, Bin WU, Ryan WURZ
  • Bicyclic compounds as Pim inhibitors
    Patent number: 9090593
    Abstract: The invention relates to bicyclic compounds of formula (1?), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: July 28, 2015
    Assignee: AMGEN INC.
    Inventors: Hui-Ling Wang, Kaustav Biswas, Victor J. Cee, Frank Chavez, Jr., Bradley J. Herberich, Claire L. M. Jackson, Brian A. Lanman, Matthew Lee, Thomas Nixey, Liping H. Pettus, Anthony B. Reed, Robert M. Rzasa, Shannon Rumfelt, Andrew Tasker, Bin Wu, Ryan Wurz
  • Inhibitors of PI3 kinase and/or mTOR
    Patent number: 8772480
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: July 8, 2014
    Assignee: Amgen Inc.
    Inventors: Kristin L. Andrews, Yunxin Y. Bo, Shon Booker, Victor J. Cee, Noel D'Angelo, Bradley J. Herberich, Fang-Tsao Hong, Claire L. M. Jackson, Brian Alan Lanman, Hongyu Liao, Longbin Liu, Nobuko Nishimura, Mark H. Norman, Liping H. Pettus, Anthony B. Reed, Adrian Leonard Smith, Seifu Tadesse, Nuria A. Tamayo, Bin Wu, Ryan Wurz, Kevin C. Yang
  • Azole Compounds as PIM Inhibitors
    Publication number: 20140187553
    Abstract: The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Application
    Filed: March 21, 2012
    Publication date: July 3, 2014
    Applicant: AMGEM INC.
    Inventors: Hui-Ling Wang, Victor J. Cee, Bradley J. Herberich, Claire L.M. Jackson, Brian Alan Lanman, Thomas Nixey, Liping H. Pettus, Anthony B. Reed, Bin Wu, Ryan Wurz, Andrew Tasker
  • BICYCLIC COMPOUNDS AS PIM INHIBITORS
    Publication number: 20140031360
    Abstract: The invention relates to bicyclic compounds of formula (1?), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Application
    Filed: December 7, 2011
    Publication date: January 30, 2014
    Applicant: AMGEN INC.
    Inventors: Hui-Ling Wang, Kaustav Biswas, Victor J. Cee, Frank Chavez, JR., Bradley J. Herberich, Claire L.M. Jackson, Brian A. Lanman, Matthew Lee, Thomas Nixey, Liping H. Pettus, Anthony B. Reed, Robert M. Rzasa, Shannon Rumfelt, Andrew Tasker, Bin Wu, Ryan Wurz
  • Azaquinolones that inhibit prolyl hydroxylase
    Patent number: 8349868
    Abstract: Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: January 8, 2013
    Assignee: Amgen Inc.
    Inventors: Jennifer R. Allen, Roland Burli, Marian C. Bryan, Guo-Qiang Cao, Susana C. Neira, Anthony B. Reed
  • Quinolones and azaquinolones that inhibit prolyl hydroxylase
    Patent number: 8048894
    Abstract: Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: April 16, 2008
    Date of Patent: November 1, 2011
    Assignee: Amgen Inc.
    Inventors: Jennifer R. Allen, Roland Burli, Marian C. Bryan, Guo-Qiang Cao, Susana C. Neira, Anthony B. Reed
  • Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
    Patent number: 8030346
    Abstract: Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: October 4, 2011
    Assignee: Amgen Inc.
    Inventors: Jennifer R. Allen, Roland Burli, Michael J. Frohn, Randall W. Hungate, Susana C. Neira, Anthony B. Reed